Choosing Between Patents and Trade Secrets: A Founder's Decision Framework for IP-Driven Valuation

Founders must strategically choose between patents and trade secrets based on technology type, defensibility, and funding stage to maximize IP-driven valuation and attract deep-tech investors. Aligning IP protection with the fundraising journey is crucial for success.

Mina Kim

October 30, 2026 · 5 min read

The Strategic Imperative of IP for Deep-Tech Startups

Deep-tech and biotech ventures differ from software-as-a-service businesses in a fundamental way: their value often sits in the underlying invention rather than in distribution or growth metrics. That changes what investors ask. As Radhakrishnan puts it, whether a company is preparing for its first seed round or entering a strategic acquisition, investors and potential buyers will inevitably ask what the startup owns and how protected it is.

Guidance published by IfM Engage, the knowledge-transfer arm of the University of Cambridge's Institute for Manufacturing, frames IP strategy development as a practice startups should use to maximize value from their IP, and points to its role in helping young companies turn innovative ideas into viable businesses. In other words, IP is not a legal afterthought bolted onto a finished product; it is part of how the company is built and how it is eventually priced.

That framing has practical consequences for founders. A patent or a well-managed trade secret portfolio signals more than legal protection—it signals business discipline. Specialist fundraising guidance for IP-backed startups argues that to a specialist investor, your IP strategy signals your business acumen, your technical depth, and your ability to build a durable monopoly. The same source is blunt about the mindset shift required: "Stop thinking like a lawyer; start thinking like a capitalist."

IP as a Valuation Multiplier: What Investors Seek

The strongest form of protection for deep tech is the utility patent, which the fundraising guidance describes as a 20-year government-granted monopoly on a novel invention—covering how the invention works, whether that is a new chemical process or a machine learning method, and calling it the gold standard for deep tech and biotech. That monopoly framing matters to investors because it converts technical novelty into an assessable, time-limited competitive barrier.

Trade secrets function differently but can serve a comparable role in the portfolio. The guidance is explicit that a startup's IP portfolio is more than just patents and recommends a multi-layered defense in which founders understand what they have and how each piece contributes to their competitive barrier. Both utility and design patents and trade secrets sit inside that layered structure.

Timing shapes investor perception as much as portfolio composition. Practitioner guidance for IP-backed startups warns that delaying patent filing can significantly lower valuations or sink deals, and that failing to protect trade secrets early can have a similar negative effect on deals and valuations. The corollary: a startup that arrives at a seed or Series A conversation with its IP already structured removes a category of risk the investor would otherwise price in.

Which investors respond to this matters as much as the IP itself. The fundraising guidance advises that once a startup has technical validation—often from grant funding—and a clear IP moat, it should target deep-tech venture capital at the seed and Series A stages, since most generalist SaaS investors will pass. It names firms such as Lux Capital, DCVC, Playground Global, and Founders Fund as examples of funds comfortable with technical risk and long timelines, and suggests researching whether their portfolios include other IP-heavy hardware, biotech, or enterprise platform companies before pitching.

Your IP Strategy Decision Framework

The framework below maps the dimensions that, according to the sources, drive the patent-versus-trade-secret choice: the nature of the innovation, the business model and competitive landscape, and the fundraising stage. Guidance on IP strategy development from IfM Engage supports the premise that the choice depends on these characteristics and must align with overall business objectives to affect commercialization success. For structuring the decision itself, materials from the IP Business Academy's CEIPI Master Program module on decision theory and IP valuation note that decision trees help decision-makers map out scenarios and understand the range of possible outcomes, an approach described as particularly valuable for early-stage technologies where outcomes are highly uncertain.

IP strategy decision matrix: mapping startup characteristics to recommended approaches
Dimension	Question to answer	What the evidence suggests	Direction it points
Technology type	Is the core asset a novel process, machine, or formulation?	Utility patents are described as the gold standard for deep tech and biotech, protecting how the invention works	Patent-leaning for hardware, biotech, and novel processes
Defensibility	Can the invention be kept confidential through operations, or is it exposed once shipped?	Guidance recommends a multi-layered defense in which each IP asset contributes to the competitive barrier	Exposed inventions favor patents; internally held methods can lean on trade secrets within a layered portfolio
Fundraising stage	Are you seeking grants and technical validation, or seed/Series A venture capital?	Deep-tech VCs are advised targets once technical validation and a clear IP moat exist	Early: validate and structure the moat; Seed/Series A: present a structured portfolio to specialists
Timing	Are protections already in place before the raise?	Delaying patent filing can significantly lower valuations or tank deals; unprotected trade secrets carry the same warning	File or implement protocols before, not during, investor diligence
Investor fit	Does the target fund hold IP-heavy portfolio companies?	Firms like Lux Capital, DCMC-style deep-tech specialists, Playground Global, and Founders Fund are cited as comfortable with technical risk	Prioritize deep-tech specialists over generalist SaaS funds

To use the matrix, work down the left column and note which direction each answer points. A hypothetical illustration shows the reasoning path: a startup with a machine learning method that can be reverse-engineered from the shipped product, raising a Series A, would see the technology-type and defensibility rows point toward a patent filing—the evidence describes utility patents as protecting exactly that class of invention—while the timing row demands the filing precede the raise. A startup whose value sits in an internally held process that customers never see could justify a trade-secret-first approach inside the layered portfolio the guidance recommends, provided early protection is demonstrable to investors.

For genuinely uncertain outcomes, the IP Business Academy materials support adding a probability-weighted step: expected-value calculations that weight potential outcomes by their probability of occurrence form the backbone of many IP valuation methods and are described as particularly useful for early-stage technologies, allowing assessment of both upside potential and downside risk. This is a strategic guide, not a substitute for legal advice, due diligence, or professional consultation.

Implementing Your IP Strategy for Fundraising Success

Execution turns the framework into valuation. The first step is an honest inventory: identify every patentable invention, protectable secret, and design element, and place each within the layered defense the fundraising guidance describes. The second step is sequencing around the raise. Because the practitioner guidance warns that delayed patent filing and neglected trade secret protection both depress valuations and can end deals, protections should be in place before the funding conversation, not negotiated into it afterward.

The third step is matching the pitch to the investor. The guidance recommends approaching specialist deep-tech funds only after technical validation—often supported by grant funding—and a clear IP moat are in place, and researching each fund's portfolio for comparable IP-heavy companies. Founders should also note what the sources do not settle: the retained guidance does not specify how investor expectations differ between a provisional filing and a granted patent at each stage, so founders should expect diligence questions and prepare to explain their filing posture rather than assume a single standard.

Finally, treat the strategy as evolving. The fundraising guidance describes a progression from non-dilutive funding toward venture capital, which implies the IP portfolio and its presentation should mature alongside the company rather than remain static from the seed deck to the Series A data room.